Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 19

1.

Absence of Ischemic Injury after Sacrificing the Superior Petrosal Vein during Microvascular Decompression.

Xia Y, Kim TY, Mashouf LA, Patel KK, Xu R, Casaos J, Choi J, Kim ES, Hung AL, Wu A, Garzon-Muvdi T, Bender MT, Jackson CM, Bettegowda C, Lim M.

Oper Neurosurg (Hagerstown). 2019 Jun 19. pii: opz163. doi: 10.1093/ons/opz163. [Epub ahead of print]

PMID:
31214696
2.

Combination anti-CXCR4 and anti-PD-1 immunotherapy provides survival benefit in glioblastoma through immune cell modulation of tumor microenvironment.

Wu A, Maxwell R, Xia Y, Cardarelli P, Oyasu M, Belcaid Z, Kim E, Hung A, Luksik AS, Garzon-Muvdi T, Jackson CM, Mathios D, Theodros D, Cogswell J, Brem H, Pardoll DM, Lim M.

J Neurooncol. 2019 Jun;143(2):241-249. doi: 10.1007/s11060-019-03172-5. Epub 2019 Apr 25.

PMID:
31025274
3.

Retrosigmoid approach for glycerin rhizotomy in the treatment of trigeminal neuralgia without overt arterial compression: updated case series.

Kim TY, Jackson CM, Xia Y, Mashouf LA, Patel KK, Kim ES, Hung AL, Wu A, Garzon-Muvdi T, Bender MT, Bettegowda C, Lee JYK, Lim M.

J Neurosurg. 2019 Mar 8:1-7. doi: 10.3171/2018.12.JNS182572. [Epub ahead of print]

PMID:
30849763
4.

Fire in the Smoke: Battling Brain Tumors.

Lim M, Jackson CM.

Cerebrum. 2018 May 1;2018. pii: cer-07-18. eCollection 2018 May-Jun.

5.

Contrasting impact of corticosteroids on anti-PD-1 immunotherapy efficacy for tumor histologies located within or outside the central nervous system.

Maxwell R, Luksik AS, Garzon-Muvdi T, Hung AL, Kim ES, Wu A, Xia Y, Belcaid Z, Gorelick N, Choi J, Theodros D, Jackson CM, Mathios D, Ye X, Tran PT, Redmond KJ, Brem H, Pardoll DM, Kleinberg LR, Lim M.

Oncoimmunology. 2018 Sep 6;7(12):e1500108. doi: 10.1080/2162402X.2018.1500108. eCollection 2018.

6.

Dendritic cell activation enhances anti-PD-1 mediated immunotherapy against glioblastoma.

Garzon-Muvdi T, Theodros D, Luksik AS, Maxwell R, Kim E, Jackson CM, Belcaid Z, Ganguly S, Tyler B, Brem H, Pardoll DM, Lim M.

Oncotarget. 2018 Apr 17;9(29):20681-20697. doi: 10.18632/oncotarget.25061. eCollection 2018 Apr 17.

7.

Immunotherapy for Glioblastoma: Playing Chess, Not Checkers.

Jackson CM, Lim M.

Clin Cancer Res. 2018 Sep 1;24(17):4059-4061. doi: 10.1158/1078-0432.CCR-18-0491. Epub 2018 Apr 24.

PMID:
29691293
8.

Clinical Trials Investigating Immune Checkpoint Blockade in Glioblastoma.

Maxwell R, Jackson CM, Lim M.

Curr Treat Options Oncol. 2017 Aug;18(8):51. doi: 10.1007/s11864-017-0492-y. Review.

PMID:
28785997
9.

Anti-PD-1 antitumor immunity is enhanced by local and abrogated by systemic chemotherapy in GBM.

Mathios D, Kim JE, Mangraviti A, Phallen J, Park CK, Jackson CM, Garzon-Muvdi T, Kim E, Theodros D, Polanczyk M, Martin AM, Suk I, Ye X, Tyler B, Bettegowda C, Brem H, Pardoll DM, Lim M.

Sci Transl Med. 2016 Dec 21;8(370):370ra180. doi: 10.1126/scitranslmed.aag2942.

10.

Combination Therapy with Anti-PD-1, Anti-TIM-3, and Focal Radiation Results in Regression of Murine Gliomas.

Kim JE, Patel MA, Mangraviti A, Kim ES, Theodros D, Velarde E, Liu A, Sankey EW, Tam A, Xu H, Mathios D, Jackson CM, Harris-Bookman S, Garzon-Muvdi T, Sheu M, Martin AM, Tyler BM, Tran PT, Ye X, Olivi A, Taube JM, Burger PC, Drake CG, Brem H, Pardoll DM, Lim M.

Clin Cancer Res. 2017 Jan 1;23(1):124-136. doi: 10.1158/1078-0432.CCR-15-1535. Epub 2016 Jun 29.

11.

Erratum to: PD-1, PD-L1, PD-L2 expression in the chordoma microenvironment.

Mathios D, Ruzevick J, Jackson CM, Xu H, Shah SR, Taube JM, Burger PC, McCarthy EF, Quinones-Hinojosa A, Pardoll DM, Lim M.

J Neurooncol. 2016 May;128(1):183. doi: 10.1007/s11060-016-2130-0. No abstract available.

PMID:
27161248
12.

Systemic Tolerance Mediated by Melanoma Brain Tumors Is Reversible by Radiotherapy and Vaccination.

Jackson CM, Kochel CM, Nirschl CJ, Durham NM, Ruzevick J, Alme A, Francica BJ, Elias J, Daniels A, Dubensky TW Jr, Lauer P, Brockstedt DG, Baxi EG, Calabresi PA, Taube JM, Pardo CA, Brem H, Pardoll DM, Lim M, Drake CG.

Clin Cancer Res. 2016 Mar 1;22(5):1161-72. doi: 10.1158/1078-0432.CCR-15-1516. Epub 2015 Oct 21.

13.

Lymphocyte Activation Gene 3 (LAG-3) modulates the ability of CD4 T-cells to be suppressed in vivo.

Durham NM, Nirschl CJ, Jackson CM, Elias J, Kochel CM, Anders RA, Drake CG.

PLoS One. 2014 Nov 5;9(11):e109080. doi: 10.1371/journal.pone.0109080. eCollection 2014.

14.

PD-1, PD-L1, PD-L2 expression in the chordoma microenvironment.

Mathios D, Ruzevick J, Jackson CM, Xu H, Shah SR, Taube JM, Burger PC, McCarthy EF, Quinones-Hinojosa A, Pardoll DM, Lim M.

J Neurooncol. 2015 Jan;121(2):251-9. doi: 10.1007/s11060-014-1637-5. Epub 2014 Oct 28. Erratum in: J Neurooncol. 2016 May;128(1):183.

15.

Immunotherapy for brain cancer: recent progress and future promise.

Jackson CM, Lim M, Drake CG.

Clin Cancer Res. 2014 Jul 15;20(14):3651-9. doi: 10.1158/1078-0432.CCR-13-2057. Epub 2014 Apr 25. Review.

16.

STAT3 Activation in Glioblastoma: Biochemical and Therapeutic Implications.

Kim JE, Patel M, Ruzevick J, Jackson CM, Lim M.

Cancers (Basel). 2014 Feb 10;6(1):376-95. doi: 10.3390/cancers6010376.

17.

Sequencing CTLA-4 blockade with cell-based immunotherapy for prostate cancer.

Wada S, Jackson CM, Yoshimura K, Yen HR, Getnet D, Harris TJ, Goldberg MV, Bruno TC, Grosso JF, Durham N, Netto GJ, Pardoll DM, Drake CG.

J Transl Med. 2013 Apr 4;11:89. doi: 10.1186/1479-5876-11-89.

18.

Anti-PD-1 blockade and stereotactic radiation produce long-term survival in mice with intracranial gliomas.

Zeng J, See AP, Phallen J, Jackson CM, Belcaid Z, Ruzevick J, Durham N, Meyer C, Harris TJ, Albesiano E, Pradilla G, Ford E, Wong J, Hammers HJ, Mathios D, Tyler B, Brem H, Tran PT, Pardoll D, Drake CG, Lim M.

Int J Radiat Oncol Biol Phys. 2013 Jun 1;86(2):343-9. doi: 10.1016/j.ijrobp.2012.12.025. Epub 2013 Feb 22.

19.

Strain-specific induction of experimental autoimmune prostatitis (EAP) in mice.

Jackson CM, Flies DB, Mosse CA, Parwani A, Hipkiss EL, Drake CG.

Prostate. 2013 May;73(6):651-6. doi: 10.1002/pros.22606. Epub 2012 Nov 5.

Supplemental Content

Loading ...
Support Center